CoChat

Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen

Open access

Published version of a preprint

The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.

Abstract

Vemurafenib is a BRAF kinase inhibitor (BRAFi) that is used to treat melanoma patients harboring the constitutively active BRAF-V600E mutation. However, after a few months of treatment patients often develop resistance to vemurafenib leading to disease progression. Sequence analysis of drug-resistant tumor cells and functional genomic screens has identified several genes that regulate vemurafenib resistance. Reactivation of mitogen-activated protein kinase (MAPK) pathway is a recurrent feature of cells that develop resistance to vemurafenib. We performed a genome-scale CRISPR-based knockout screen to identify modulators of vemurafenib resistance in melanoma cells with a highly improved CRISPR sgRNA library called Brunello. We identified 33 genes that regulate resistance to vemurafenib out of which 14 genes have not been reported before. Gene ontology enrichment analysis showed that the hit genes regulate histone modification, transcription and cell cycle. We discuss how inactivation of hit genes might confer resistance to vemurafenib and provide a framework for follow-up investigations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/g3journal/jkaa069

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic representation of the workflow for the genome-wide CRISPR/Cas9 screen. HEK293FT cells were transfected with lentiviral CRISPR-Cas9 plasmid library (Brunello library with genome wide coverage and 4 sgRNAs per gene) for lentivirus production. A375 cells were then transduced with lentiviruses generated from the Brunello plasmid library. Cells were selected for successful transduction using puromycin selection for 7 days. After that, cells were either treated with 2 µM vemurafenib or DMSO. Samples were collected at days 7 and 14. gDNA was prepared from the cells and the relative sgRNA abundance was determined by PCR-mediated amplification of sgRNA sequences from gDNA followed by NGS.
Figure 1 Schematic representation of the workflow for the genome-wide CRISPR/Cas9 screen. HEK293FT cells were transfected with lentiviral CRISPR-Cas9 plasmid library (Brunello library with genome wide coverage and 4 sgRNAs per gene) for lentivirus production. A375 cells were then transduced with lentiviruses generated from the Brunello plasmid library. Cells were selected for successful transduction using puromycin selection for 7 days. After that, cells were either treated with 2 µM vemurafenib or DMSO. Samples were collected at days 7 and 14. gDNA was prepared from the cells and the relative sgRNA abundance was determined by PCR-mediated amplification of sgRNA sequences from gDNA followed by NGS.CC BY · PubMed Central
Figure 2 NGS data analysis of the genome wide screen using CRISPRAnalyzeR. (A) Cell viability of A375 cells after treatment with various concentration of vemurafenib was determined using Real-time-Glo MT Cell Viability Assay. Percentage viability was plotted against various concentration of vemurafenib. Three days after vemurafenib treatment samples are indicated by circle shape while the 4 days after vemurafenib treatment samples are indicated by square shape. (B) Boxplot showing the read count distribution from individual sgRNAs for the DMSO-treated and vemurafenib-treated cells for days 7 and 14. For day 14, there is an increase in the number of reads for the most abundant sgRNAs in the vemurafenib- treated cells as compared to the DMSO treated cells. (C) Pairwise correlation plot of the day 7 samples with the Pearson and Spearman correlation coefficients. (D) Pairwise correlation plot of the day 14 samples with the Pearson and Spearman correlation coefficients.
Figure 2 NGS data analysis of the genome wide screen using CRISPRAnalyzeR. (A) Cell viability of A375 cells after treatment with various concentration of vemurafenib was determined using Real-time-Glo MT Cell Viability Assay. Percentage viability was plotted against various concentration of vemurafenib. Three days after vemurafenib treatment samples are indicated by circle shape while the 4 days after vemurafenib treatment samples are indicated by square shape. (B) Boxplot showing the read count distribution from individual sgRNAs for the DMSO-treated and vemurafenib-treated cells for days 7 and 14. For day 14, there is an increase in the number of reads for the most abundant sgRNAs in the vemurafenib- treated cells as compared to the DMSO treated cells. (C) Pairwise correlation plot of the day 7 samples with the Pearson and Spearman correlation coefficients. (D) Pairwise correlation plot of the day 14 samples with the Pearson and Spearman correlation coefficients.CC BY · PubMed Central
Figure 3 Identification of vemurafenib-resistance genes using MAGeCK. The sgRNA distribution data of DMSO-treated and vemurafenib-treated cells were analyzed by MaGeCK. For each gene, the −log10P-value was plotted against its log2 fold change. Vemurafenib resistance genes were identified using a P-value threshold of 0.05. Significant hits are denoted by red dots along with gene names. Novel hit genes are in bold red font.
Figure 3 Identification of vemurafenib-resistance genes using MAGeCK. The sgRNA distribution data of DMSO-treated and vemurafenib-treated cells were analyzed by MaGeCK. For each gene, the −log10P-value was plotted against its log2 fold change. Vemurafenib resistance genes were identified using a P-value threshold of 0.05. Significant hits are denoted by red dots along with gene names. Novel hit genes are in bold red font.CC BY · PubMed Central
Figure 4 STRING analysis and GO term enrichment analysis of the 33 hits from the CRISPR screen. (A) Shortlisted genes were analyzed using the Search Tool for the Retrieval of Interacting Genes/Proteins database (STRING v11). Network nodes represent proteins and the edges represent PPIs. Results of STRING analysis are presented in Supplementary Table S5. (B) GO term enrichment analysis was performed using DAVID. GO terms are clustered together based on semantic similarity in the 2-dimensional scatterplot. P-value which indicates the enrichment strength in the annotation category is denoted by the bubble color and the GO term frequency is denoted by the bubble size. Results of DAVID analysis are presented in Supplementary Table S6.
Figure 4 STRING analysis and GO term enrichment analysis of the 33 hits from the CRISPR screen. (A) Shortlisted genes were analyzed using the Search Tool for the Retrieval of Interacting Genes/Proteins database (STRING v11). Network nodes represent proteins and the edges represent PPIs. Results of STRING analysis are presented in Supplementary Table S5. (B) GO term enrichment analysis was performed using DAVID. GO terms are clustered together based on semantic similarity in the 2-dimensional scatterplot. P-value which indicates the enrichment strength in the annotation category is denoted by the bubble color and the GO term frequency is denoted by the bubble size. Results of DAVID analysis are presented in Supplementary Table S6.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Cited by

See all 22

Metadata

Authors
Goh, C. J. H., Wong, J. H., El Farran, C., Tan, B. X., Coffill, C. R., Loh, Y.-H., Lane, D., & Arumugam, P.
Affiliations
  • Agency for Science, Technology and Research (SG)
  • Epigenetics and Cell Fates Laboratory, A*STAR Institute of Molecular and Cell Biology, Singapore 138673, Singapore
Corresponding author
Arumugam, Prakash
Venue
G3 Genes|Genomes|Genetics
Published
2021-01-11
Volume
11
Issue
2
ISSN
2160-1836 (ISSN-L)
OpenAlex
W3129457230
Cited by
20
References
76
Citations by year
2026: 7 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 1
FWCI
1.02
Type
journal article
Language
en
Open access
Locations
  • G3 Genes Genomes Genetics (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Agency for Science, Technology and Research (A*STAR)
  • Industry Alignment Fund—Pre-Positioning Programme (H18/01/a0/B14)
  • A*STAR Innovations in Food and Chemical Safety
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Keywords
vemurafenib resistance, melanoma, BRAF V600E mutation, BRAF inhibitors, MAPK pathway reactivation, histone modifications, transcriptional regulation, cell cycle genes, drug resistance genes
MeSH terms
Vemurafenib, Humans, Melanoma, Mutation, Drug Resistance, Neoplasm, Cell Line, Tumor, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen. https://app.cochat.ai/papers/10.1093/g3journal/jkaa069
The paper
Goh, C. J. H., Wong, J. H., El Farran, C., Tan, B. X., Coffill, C. R., Loh, Y.-H., Lane, D., & Arumugam, P. (2021). Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen. G3 Genes|Genomes|Genetics. https://doi.org/10.1093/g3journal/jkaa069

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.